Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings through conference calls. Seelos focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson’s Disease.

News Market Reaction – SEEL

-3.09%

1 alert

-3.09% News Effect

On the day this news was published, SEEL declined 3.09%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020.

Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls.

For additional information about the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference: https://benchmark-healthcare-house-call-virtual.events.issuerdirect.com/

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

FAQ

What is Seelos Therapeutics participating in on June 15-16, 2020?

Seelos Therapeutics will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference.

Who will represent Seelos Therapeutics at the conference?

Raj Mehra, Ph.D., Chairman and CEO, will host meetings at the conference.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases.

What are some conditions targeted by Seelos Therapeutics?

Seelos Therapeutics targets conditions such as Acute Suicidal Ideation, Major Depressive Disorder, and Parkinson’s Disease.